SciSparc Ltd. SPRC

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
35/100
Developing

About SciSparc Ltd.

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has … Full SPRC analysis →

Competitive advantage assessment

Key risks

  • ROIC Below WACC or Peers ROIC at 16.6th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.12), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
39

Where SPRC ranks in Biotechnology

SciSparc Ltd. ranks #449 of 713 scored companies in Biotechnology by moat score — the top 63%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near SPRC in Biotechnology
# Company Moat score Rating
445 Fractyl Health, Inc. GUTS 35/100 Developing
446 Jasper Therapeutics, Inc. JSPR 35/100 Developing
447 Jasper Therapeutics, Inc. JSPRW 35/100 Developing
448 Prime Medicine, Inc. PRME 35/100 Developing
449 SciSparc Ltd. SPRC 35/100 Developing
450 Corbus Pharmaceuticals Holdings CRBP 35/100 Developing
451 Spruce Biosciences, Inc. SPRB 35/100 Developing
452 Hoth Therapeutics, Inc. HOTH 34/100 Developing
453 Sensei Biotherapeutics, Inc. SNSE 34/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How SPRC scores on the Corporate Default defenses

Pricing Power

Score 39 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 37 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 52 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 21 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 24 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 37 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding SPRC's moat

What is SciSparc Ltd.'s moat score?

SciSparc Ltd. (SPRC) scores 35 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #449 of 713 scored companies in Biotechnology, the top 63%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (52/100) and its weakest is Capital Efficiency (21/100).

How does SciSparc Ltd. compare with other Biotechnology companies?

SciSparc Ltd. ranks #449 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Prime Medicine, Inc. (PRME) at 35 just above it and Corbus Pharmaceuticals Holdings (CRBP) at 35 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is SciSparc Ltd. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for SciSparc Ltd.?

The Corporate Default template measures 6 defenses, and SPRC scores: Pricing Power (39), Cost Advantage (37), Customer Stickiness (52), Capital Efficiency (21), Resilience (24), Scale & Market Position (37). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000